Dr Sin Yong · MBBS (NUS) · MRCS (Edin) · MSc Aesthetic Medicine (London) · MSc Practical Dermatology (Cardiff) · International KOL
Deusaderm is injectable cross-linked porcine collagen with lidocaine. It is collagen placed, not collagen stimulated — a different category from Sculptra or Ellansé, and from hyaluronic acid filler. Assessed and placed by Dr Sin Yong at Orchard Road, Singapore.
Deusaderm is a collagen gel for injection, made by Sunmax Biotechnology in Taiwan from highly purified porcine skin collagen that has been cross-linked so that it resists breakdown for longer than native collagen would. It is predominantly type I collagen with a type III fraction, and the formulation includes lidocaine. Sunmax's published specification for its cross-linked porcine collagen implants with lidocaine is 35 mg of collagen and 3 mg of lidocaine hydrochloride per millilitre.
Injectable collagen is not new. Bovine collagen was the original dermal filler in the 1980s and 1990s before hyaluronic acid replaced it, partly because bovine collagen required skin testing for allergy and partly because it did not last. Porcine collagen is structurally closer to human collagen; the Sunmax trial published in 2024 states that a pre-treatment skin test is not required for its product. That is a change from the old bovine products, not an absence of risk.
The important distinction is categorical. Deusaderm places collagen. Sculptra, Ellansé and Radiesse place a scaffold and rely on the skin to build collagen around it. Marketing routinely blurs the two; they behave differently in tissue and over time.

Hyaluronic acid is hydrophilic: it draws water into itself, which is part of how it fills. In most of the face that is useful. Under the eye it is a liability. The lower-lid skin is the thinnest on the face, it sits over a loose, water-retaining tissue plane, and hyaluronic acid placed there can swell, migrate, or show as a bluish discolouration known as the Tyndall effect. The tear trough is the commonest site of filler regret for exactly these reasons.
Collagen does not draw water. Placed superficially in small amounts, it does not swell afterwards, and it is opaque rather than translucent, so it does not produce the blue tint. That is the whole clinical case for a collagen injectable in the periorbital area: not that it is stronger or longer-lasting than hyaluronic acid, but that it behaves differently in the one place where hyaluronic acid's behaviour is the problem.
What it gives up in return is reversibility. Hyaluronidase dissolves hyaluronic acid and nothing else. A collagen implant that is misplaced is resorbed on its own timeline and managed in the meantime.
The evidence base for porcine collagen fillers is thinner than for hyaluronic acid or for the established biostimulators, and it is worth being plain about that.
The principal published trial of Sunmax's cross-linked porcine collagen with lidocaine was a randomised, double-blind, multicentre study of 252 participants treated for nasolabial folds, published in Clinical, Cosmetic and Investigational Dermatology in 2024, with follow-up to 52 weeks. It compared two Sunmax formulations against each other rather than against hyaluronic acid, and it studied the nasolabial fold rather than the under-eye area where the product is most often marketed. Adverse events were common but mostly the expected injection-site findings — redness, swelling, pain, bruising, itch — and mostly resolved within a month; nodules were reported.
So the controlled evidence supports the product as a collagen filler for folds, and the periorbital use rests on clinical reasoning about how collagen behaves rather than on a trial in that area. That is a legitimate basis for a cautious, small-volume treatment; it is not a basis for the claims made about it on social media.
“Injecting collagen is not the same as stimulating it. One is a deposit the body slowly removes; the other is a process the body carries on without you.”
Dr Sin YongOn the difference between Deusaderm and a biostimulator
Dr Sin Yong uses Deusaderm narrowly. It is not a volumiser in his hands and it is not a substitute for assessing why an under-eye looks the way it does.
He begins by separating the three things that make a lower eyelid look tired, because they need different answers: a true hollow at the tear trough, a fat pad that has bulged forward above it, and thin or pigmented skin that shows the vessels and muscle beneath. Collagen addresses only the last of these with any logic. A prominent fat pad is not improved by placing anything beneath it, and a deep hollow in a young, thick-skinned face is often better served by a small amount of reversible hyaluronic acid or by leaving it alone. The causes of eye bags are set out separately.
Where collagen is the right tool, he places it superficially in small amounts with a cannula where the anatomy allows, keeps it well away from the orbital rim vessels, and reviews before adding anything. He does not layer it over previous hyaluronic acid filler that has not been mapped, and in a face with earlier injections he will usually image first. Dark circles that are pigment rather than structure are not treated with an injectable at all; they belong to a different assessment.

It suits thin, crepey lower-eyelid skin and fine periorbital or perioral lines in a patient who has understood that it cannot be dissolved, who is not allergic to collagen or pork-derived products, and who is not looking for volume. It is also a reasonable option for someone who has had a poor experience with hyaluronic acid under the eye — swelling or a blue tint — once that filler has been dissolved and the tissue has settled.
It does not suit a bulging fat pad, which is an anatomical problem, nor a deep hollow that needs structure, nor a patient with a history of autoimmune or connective-tissue disease, where any animal-derived implant deserves caution. It is not a treatment for pigmented dark circles. And it is not interchangeable with the collagen stimulators: it will not provide the gradual structural support of Sculptra or the firm definition of Ellansé.
Where the complaint is laxity of the lower lid or the mid-face rather than skin quality, an injectable of any kind is the wrong category; focused ultrasound is the relevant conversation.
A face that has been injected more than once often arrives with a complaint that sounds like it needs more product — a heaviness in the lower face, a fullness under the eyes, a lump that has appeared months after the last visit. In Dr Sin Yong's experience the opposite is more often true: the problem is what is already there, and the answer is subtraction, not addition.
So before any further Deusaderm is placed, he scans. High-frequency ultrasound shows what material is sitting in the tissue, how deep it is, whether it has migrated, and whether a lump is collagen, old hyaluronic acid filler, a cyst, or scar. Each of those is managed differently, and two of them are made worse by injecting on top. A scan takes minutes and changes the plan more often than not.
If the scan shows that less is what you need, that is a different procedure with its own planning — see filler correction. If it shows a clean field, Deusaderm can be placed with confidence rather than hope. Either way, nothing is added to a face that has not been looked beneath.
The common findings are the injection-site ones reported in the trial: redness, swelling, tenderness, bruising and itch, mostly settling within days to weeks. Small nodules are reported and are managed rather than dissolved. Allergic reaction to collagen is uncommon with porcine material but not impossible, which is why history matters even when a skin test is not required.
The serious risks are vascular and are heightened in the periorbital area, where the vessels connect to the circulation of the eye; this is the reason placement near the orbital rim is conservative and the reason who injects matters more than what is injected. Collagen is resorbed by the body over months; the change is not lifelong, and no duration quoted to you is a prediction for your skin.
Yang CY, Chang YC, Tai HC, et al. Evaluation of collagen dermal filler with lidocaine for the correction of nasolabial folds: a randomized, double-blind, multicenter clinical trial. Clinical, Cosmetic and Investigational Dermatology 2024;17:1621–1631. source
Sunmax Biotechnology. Collagen implant with lidocaine — product specification (cross-linked porcine collagen 35 mg/mL, lidocaine HCl 3 mg/mL). source
Wortsman X. Identification and complications of cosmetic fillers: sonography first. Journal of Ultrasound in Medicine 2015;34(7):1163–1172. source
Health Sciences Authority. Infosearch — register of health products and medical devices approved for supply in Singapore. source
Singapore Medical Council. Guidelines on Aesthetic Practices for Doctors, 2016 Edition. source
Medically reviewed by Dr Sin Yong, MBBS (NUS), MRCS (Edinburgh) · Last updated 2 October 2026
A tired lower eyelid can be a hollow, a fat pad or thin skin, and only one of those is answered by collagen. Dr Sin Yong assesses which before anything is placed.
Arrange a consultation